Drotrecogin alfa (activated) in the treatment of severe sepsis

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 4, 2006, Pages 537-547

  Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Anti inflammatory; Anticoagulant; Drotrecogin alfa; Organ failure; Septic shock; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; COMPLEMENT COMPONENT C4B; D DIMER; DROTRECOGIN; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APACHE; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBRINOLYSIS; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; LICENCE; MORTALITY; NEUTROPHIL CHEMOTAXIS; PROTEIN SYNTHESIS; RISK ASSESSMENT; SEPSIS; TREATMENT OUTCOME;

ANIMALS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 33749515961     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.4.537     Document Type: Article

References (97)

1. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med. 34, 344-353 (2006).
2. Alberti C, Brun-Buisson C, Burchardi H et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 28, 108-121 (2002).
3. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 30, 580-588 (2004).
4. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
5. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250-1256 (2003).
6. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 (2001).
7. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003).
8. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit. Care 10, R42 (2006).
9. Abraham E, Anzuero A, Gutierrez G et al. Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 351, 929-933 (1998).
10. Opal SM, Fisher CJ Jr, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. 25, 1115-1124 (1997).
11. Dhainaut JF, Tenaillon A, Hemmer M et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 sepsis investigator group. Crit. Care Med. 26, 1963-1971 (1998).
12. Bone RC. Why sepsis trials fail. JAMA 276, 565-566 (1996).
13. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med. 25, 556-566 (1999).
14. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J. Biol. Chem. 251, 355-363 (1976).
15. Kisiel W. Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. J. Clin. Invest, 64, 761-769 (1979).
16. van de Poel RH, Meijers JC, Bouma BN. The interaction between anticoagulant protein S and complement regulatory C4b-binding protein (C4BP). Trends Cardiovasc. Med. 10, 71-76 (2000).
17. Krishnamurti C, Young GD, Barr CF, Colleton CA, Alving BM. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits. J. Lab. Clin. Med. 118, 523-530 (1991).
18. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 88, 2093-2100 (1996).
19. Alberio L, Lammle B, Esmon CT. Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin, Infect. Dis. 32, 1338-1346 (2001).
20. Hesselvik JF, Malm J, Dahlback B, Blomback M. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb. Haemost. 65, 126-129 (1991).
21. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101, 816-823 (1992).
22. Leclerc F, Hazelzet J, Jude B etal. Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med. 18, 202-205 (1992).
23. Mesters RM, Helterbrand J, Utterback BG et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit. Care Med. 28, 2209-2216 (2000).
24. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120, 915-922 (2001).
25. Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Crit. Care Med. 32, S223-S228 (2004).
26. Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin. Thromb. Hemost. 25, 537-541 (1999).
27. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J. Pediatr. 126, 646-652 (1995).
28. Rintala E, Kauppila M, Seppala OP et al. Protein C substitution in sepsis-associated purpura fulminans. Crit. Care Med. 28, 2373-2378 (2000).
29. Smith OP, White B, Vaughan D et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 350, 1590-1593 (1997).
30. Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura falminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 91, 418-422 (1993).
31. Leclerc F, Cremer R, Leteurtre S, Martinot A, Fourier C. Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock. Crit. Care Med. 28, 1694-1697 (2000).
32. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit. Care Med. 29, S69-S74 (2001).
33. Faust SN, Levin M, Harrison OB et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med. 345, 408-416 (2001).
34. Taylor FB, Chang A, Esmon CT D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. coli in the baboon. J. Clin. Invest. 79, 918-924 (1987).
35. Roback MG, Stack AM, Thompson C, Brugnara C, Schwarz HP, Saladino RA. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock 9, 138-142 (1998).
36. Aoki Y, Ota M, Katsuura Y, Komoriya K, Nakagaki T. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats. Arzneimittelforschung 50, 809-815 (2000).
37. Murakami K, Okajima K, Uchiba M et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am. J. Physiol. 272, L197-L202 (1997).
38. Dhainaut JF, Yan SB, Margolis BD et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb. Haemost. 90, 642-653 (2003).
39. Macias WL, Yau SB, Williams MD et al. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit. Care 9(Suppl. 4), S38-S45 (2005).
40. White B, Schmidt M, Murphy C et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF-κB) and tumour necrosis factor α (TNF-α) production in the THP-1 monocytic cell line. Br. J. Haematol. 110, 130-134 (2000).
41. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102, 2093-2098 (2003).
42. Kalil AC, Coyle SM, Um JY et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21, 222-229 (2004).
43. Nick JA, Coldren CD, Geraci MW et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104, 3878-3885 (2004).
44. Zeng W, Matter WF, Yan SB, Um SL, Vlahos CJ, Liu L. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit. Care Med. 32, S302-S308 (2004).
45. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105, 3178-3184 (2005).
46. Finigan JH, Dudek SM, Singleton PA et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J. Biol. Chem. 280, 17286-17293 (2005).
47. Isobe H, Okajima K, Uchiba M et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 104, 1171-1175 (2001).
48. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem. J. 373(Pt 1), 65-70 (2003).
49. Riewald M, Petrovan RJ, Donner A, Ruf W. Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. J. Endotoxin Res. 9, 317-321 (2003).
50. Feistritzer C, Mosheimer BA, Sturn DH, Riewald M, Patsch JR, Wiedermann CJ. Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. J. Immunol. 176, 1019-1025 (2006).
51. Hoffmann JN, Vollmar B, Laschke MW et al. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit. Care Med. 32, 1011-1017 (2004).
52. Hoffmann JN, Vollmar B, Laschke MW, Fertmann JM, Jauch KW, Menger MD. Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. Crit. Care 9(Suppl. 4), S33-S37 (2005).
53. Iba T, Kidokoro A, Fukunaga M, Nagakari K, Shirahama A, Ida Y. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit. Care Med. 33, 368-372 (2005).
54. Macias WL, Dhainaut JF, Yan SC et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin. Pharmacol. Ther. 72, 391-402 (2002).
55. Levy H, Small D, Heiselman DE et al. Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis. Ann. Pharmacother. 39, 262-267 (2005).
56. Bernard GR, Ely EW, Wright TJ et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit. Care Med. 29, 2051-2059 (2001).
57. Vincent JL, Angus DC, Artigas A et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit. Care Med. 31, 834-840 (2003).
58. Carlet J. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise. Crit. Care Med. 34, 525-529 (2006).
59. Laterre PF, Levy H, Clermont G et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit. Care Med. 32, 2207-2218 (2004).
60. Angus DC, Laterre PF, Helterbrand J et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit. Care Med. 32, 2199-2206 (2004).
61. Vincent JL, Bernard GR, Beale R et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE. Crit. Care Med. 33, 2266-2277 (2005).
62. Vincent JL, O'Brian J, Wheeler A et al. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit. Care 10, R74 (2006) (Epub ahead of print).
63. Abraham E, Laterre PF, Garg R et al. Drotrecogin alfa [activated] for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353, 1332-1341 (2005).
64. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N. Engl. J. Med. 347, 1030-1034 (2002).
65. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of dyotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit. Care 7, 155-163 (2003).
66. Farmer JC. Drotrecogin alfa (activated) treatment in severe sepsis: a "journal club" review of the global ENHANCE trial. Crit. Care Med. 33, 2428-2431 (2005).
67. Goldstein B, Nadel S, Peters M et al. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr. Crit. Care Med, 7(3), 200-211 (2006).
68. Macias WL. Activated protein C: do more survive? Intensive Care Med. 32, 605-607 (2006).
69. Angus DC, Linde-Zwirble WT, Clermont G et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit. Care Med. 31, 1-11 (2003).
70. Green C, Dinnes J, Takeda A et al. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol. Assess. 9(11), 1-126, iii-iv (2005).
71. Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus DC. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia 60, 155-162 (2005).
72. Manus BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347, 993-1000 (2002).
73. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J. Crit. Care 18, 217-227 (2003).
74. Dellinger RP. Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis. Crit. Care 10, 114 (2006).
75. Mackenzie AF. Activated protein C: do more survive? Intensive Care Med. 31, 1624-1626 (2005).
76. Friedrich JO, Adhikari NK, Meade MO. Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? Crit. Care 10, 145 (2006).
77. LaRosa SP. Drotrecogin alfa (activated) in severe sepsis. N. Engl. J. Med. 354, 94-96 (2006).
78. Mackenzie AF. Conflict of opinion - is PROWESS real progress? Intensive Care Med. 32, 610-612 (2006).
79. Abraham E, Laterre PF. Drotrecogin alfa (activated) in severe sepsis: the authors reply. N. Engl. J. Med 354, 95-96 (2006).
80. Vincent JL. Evidence-based medicine in the ICU: important advances and limitations. Chest 126, 592-600 (2004).
81. Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Crit. Care Med. 33, 2426-2428 (2005).
82. Friedrich JO. Drotrecogin alfa (activated) in severe sepsis. N. Engl. J. Med. 354, 94-96 (2006).
83. Dellinger RP, Carlet JM, Masur H et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 32, 858-873 (2004).
84. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286, 1869-1878 (2001).
85. Abraham E, Reinhart K, Opal S et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238-247 (2003).
86. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am. J. Respir. Crit. Care Med. 166, 98-104 (2002).
87. Spronk PE, Ince C, Gardien MJ, Mathura KR, Oudemans-van Straaten HM, Zandstra DF. Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet 360, 1395-1396 (2002).
88. Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent J-L. Persistant microvasculatory alterations are associated with organ failure and death in patients with septic shock. Crit. Care Med. 32, 1825-1831 (2004).
89. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit. Care Med. 34(7), 1918-1924 (2006).
90. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288, 862-871 (2002).
91. Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patient. N. Engl. J. Med. 345, 1359-1367 (2001).
92. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104, 1740-1744 (2004).
93. Gordon BR, Parker TS, Levine DM et al. Neutralization of endotoxin by a phospholipid emulsion in healthy volunteers. J. Infect. Dis. 191, 1515-1522 (2005).
94. Hotchkiss RS, Chang KC, Swanson PE et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nature Immunol. 1, 496-501 (2000).
95. Ii M, Matsunaga N, Hazeki K et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl] cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits Toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 69, 1288-1295 (2006).
96. Delgado M, Martinez C, Pozo D et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. 162, 1200-1205 (1999).
97. Hopf HW. Molecular diagnostics of injury and repair responses in critical illness: what is the future of monitoring in the intensive care unit? Crit. Care Med. 31, S518-S523 (2003).